Published on Web 09/24/2005
Divergent Enantioselective Synthesis of (-)-Galanthamine
and (-)-Morphine
Barry M. Trost,* Weiping Tang, and F. Dean Toste
Contribution from the Department of Chemistry, Stanford UniVersity, Stanford, California 94305
Received July 5, 2005; E-mail: bmtrost@stanford.edu
Abstract: An efficient divergent synthetic strategy for the synthesis of the opiate and amaryllidaceae alkaloids
emerges by employing a Pd-catalyzed asymmetric allylic alkylation (AAA) to set the stereochemistry. Three
generations of syntheses of galanthamine are discussed in detail with particular focus on the scope of the
palladium-catalyzed AAA reactions and intramolecular Heck reactions. The pivotal tricyclic intermediate is
available in six steps from 2-bromovanillin and the monoester of methyl 6-hydroxycyclohexene-1-carboxylate.
This intermediate requires only two steps to convert to (-)-galanthamine. Using a Heck vinylation, we
found that the fourth ring of codeine/morphine could be formed. The final ring formation involves a novel
visible light-promoted hydroamination. Thus, six steps are required to convert the pivotal tricyclic intermediate
into codeine, which has been demethylated in high yield to morphine.
reported using biomimetic oxidative phenol coupling17-31 to
Introduction
create the critical spiro quaternary carbon of narwedine (2),
Galanthamine (1; Figure 1),1,2 the parent member of the
galanthamine-type amaryllidaceae alkaloids (e.g. 1-3), is a
centrally acting reversible inhibitor of acetylcholinesterase
(Ache), which significantly enhances cognitive functions of
Alzheimer’s patients.3-8 It was first approved in Austria and
most recently in the rest of Europe and United States for the
treatment of Alzheimer’s disease. In the endeavor of searching
for more potent inhibitors of Ache, there is considerable interest
in derivatives which are based on (-)-galanthamine as a lead
structure9,10 since (-)-galanthamine is less toxic than other Ache
inhibitors, such as physostigmine and tacrine.9,11-13 Among
them, galanthamine derivatives 4 12-14 and its iminium salt,
synthesized by selective N-demethylation followed by N-
alkylation of galanthamine,15 were found to be more potent (up
to 70-fold) than galanthamine in inhibiting Ache.
which is converted into 1 by diastereoselective reduction.16 We
disclosed the first enantioselective synthesis of (-)-1 using a
sequential palladium-catalyzed asymmetric allylic alkylation
(AAA) and intramolecular Heck cyclization.32,33 At the same
time, several other groups utilized similar Heck cyclizations to
construct the quaternary carbon center of (()-3-deoxygalan-
thamine34,35 and (()-galanthamine 1.36 Up to now, however,
syntheses employing the oxidative phenol coupling step have
(16) Shieh, W.-C.; Carlson, J. A. J. Org. Chem. 1994, 59, 5463.
(17) Kueenburg, B.; Czollner, L.; Froehlich, J.; Jordis, U. Org. Process Res.
DeV. 1999, 3, 425.
(18) Barton, D. H. R.; Kirby, G. W. J. Chem. Soc. 1962, 806.
(19) Kametani, T.; Yamaki, K.; Yagi, H.; Fukumoto, K. J. Chem. Soc. D 1969,
425.
(20) Kametani, T.; Yamaki, K.; Yagi, H.; Fukumoto, K. J. Chem. Soc. C 1969,
2602.
(21) Kametani, T.; Yamaki, K.; Terui, T. J. Heterocycl. Chem. 1973, 10, 35.
(22) Shimizu, K.; Tomioka, K.; Yamada, S.; Koga, K. Heterocycles 1977, 8,
277.
Because of the limited supplies and the high cost of its
isolation from natural sources,16,17 several syntheses have been
(23) Shimizu, K.; Tomioka, K.; Yamada, S.; Koga, K. Chem. Pharm. Bull. 1978,
26, 3765.
(1) Hoshino, O. The Alkaloids; Academic Press: New York, 1998; Vol. 51.
(2) Martin, S. F. The Alkaloids; Academic Press: New York, 1987; Vol. 30.
(3) Weinstock, M. CNS Drugs 1999, 12, 307.
(24) Krikorian, D.; Vlahov, R.; Parushev, S.; Chinova, M.; Vlahov, I.; Schaefer,
H. J.; Duddeck, H.; Snatzke, G. Tetrahedron Lett. 1984, 25, 2969.
(25) Vlahov, R.; Krikorian, D.; Spassov, G.; Chinova, M.; Vlahov, I.; Parushev,
S.; Snatzke, G.; Ernst, L.; Kieslich, K.; Abraham, W. R.; Sheldrick, W. S.
Tetrahedron 1989, 45, 3329.
(4) Thatte, U. Curr. Opin. Cent. Peripher. NerV. Syst. InVest. Drugs 1999, 1,
357.
(5) Unni, K. CNS Drugs 1998, 10, 447.
(6) Nordberg, A.; Svensson, A.-L. Drug Saf. 1998, 19, 465.
(7) Rainer, M. Drugs Today 1997, 33, 273.
(26) Szewczyk, J.; Wilson, J. W.; Lewin, A. H.; Carroll, F. I. J. Heterocycl.
Chem. 1995, 32, 195.
(8) Mucke, H. A. M. Drugs Today 1997, 33, 251.
(9) Han, S. Y.; Sweeney, J. E.; Bachman, E. S.; Schweiger, E. J.; Forloni, G.;
Coyle, J. T.; Davis, B. M.; Joullie, M. M. Eur. J. Med. Chem. 1992, 27,
673.
(10) Bores, G. M.; Kosley, R. W., Jr. Drugs Future 1996, 21, 621.
(11) Han, S. Y.; Mayer, S. C.; Schweiger, E. J.; Davis, B. M.; Joullie, M. M.
Bioorg. Med. Chem. Lett. 1991, 1, 579.
(12) Mary, A.; Renko, D. Z.; Guillou, C.; Thal, C. Bioorg. Med. Chem. 1998,
6, 1835.
(13) Guillou, C.; Mary, A.; Renko, D. Z.; Gras, E.; Thal, C. Bioorg. Med. Chem.
Lett. 2000, 10, 637.
(14) Jordis, U.; Froehlich, J.; Treu, M.; Hirnschall, M.; Czollner, L.; Kaelz, B.;
Welzig, S. (Sanochemia Pharmazeutika Aktiengesellschaft, Austria) PCT
Int. Appl. Wo, 2001, p 285.
(15) Mary, A.; Renko, D. Z.; Guillou, C.; Thal, C. Tetrahedron Lett. 1997, 38,
5151.
(27) Chaplin, D. A.; Fraser, N.; Tiffin, P. D. Tetrahedron Lett. 1997, 38, 7931.
(28) Czollner, L.; Frantsits, W.; Kenburg, B.; Hedenig, U.; Frohlich, J.; Jordis,
U. Tetrahedron Lett. 1998, 39, 2087.
(29) Kita, Y.; Arisawa, M.; Gyoten, M.; Nakajima, M.; Hamada, R.; Tohma,
H.; Takada, T. J. Org. Chem. 1998, 63, 6625.
(30) Krikorian, D.; Tarpanov, V.; Parushev, S.; Mechkarova, P. Synth. Commun.
2000, 30, 2833.
(31) Node, M.; Kodama, S.; Hamashima, Y.; Baba, T.; Hamamichi, N.; Nishide,
K. Angew. Chem., Int. Ed. 2001, 40, 3060.
(32) Trost, B. M.; Toste, F. D. J. Am. Chem. Soc. 2000, 122, 11262.
(33) Trost, B. M.; Tang, W. Angew. Chem., Int. Ed. 2002, 41, 2795.
(34) Pilger, C.; Westermann, B.; Floerke, U.; Fels, G. Synlett 2000, 1163.
(35) Parsons, P. J.; Charles, M. D.; Harvey, D. M.; Sumoreeah, L. R.; Shell,
A.; Spoors, G.; Gill, A. L.; Smith, S. Tetrahedron Lett. 2001, 42, 2209.
(36) Guillou, C.; Beunard, J.-L.; Gras, E.; Thal, C. Angew. Chem., Int. Ed. 2001,
40, 4745.
9
10.1021/ja054449+ CCC: $30.25 © 2005 American Chemical Society
J. AM. CHEM. SOC. 2005, 127, 14785-14803
14785